Premenstrual Syndrome |
Premenstrual Syndrome (PMS); Premenstrual Syndrome / Pms |
Clinical Trial: Combined Hormone Replacement in Menstrually-Related Mood Disorders
This study is currently recruiting patients.
|
Purpose
The purpose of this study is to investigate the role of the hormones estrogen and progesterone in women with premenstrual syndrome (PMS).
Studies indicate that women with PMS experience improvement in symptoms following treatment with leuprolide acetate, when estrogen and progesterone levels are low. Women with PMS, but not women without the disorder, experience a return of symptoms within approximately a week after re-exposure to either estrogen or progesterone. The cause of this hormone-induced depression remains unclear. It is not known whether this depressed mood is due simply to the change in the levels of estrogen and progesterone and whether it would remit following continued exposure to stable levels of estrogen and progesterone. This study will determine whether the maintenance of stable hormone levels will prevent mood disturbances in women with PMS.
Participants in this study will receive leuprolide acetate injections once a month for up to 6 months. After 2 months, women whose symptoms have improved will receive a skin patch containing either estrogen or placebo (an inactive substance) and will be asked to take daily suppositories containing either progesterone or placebo. Women whose symptoms of PMS do not respond to leuprolide treatment after 2 months will end the study and be offered other treatment. Participants will be seen by a nurse in the clinic every two weeks and will fill out ratings and have blood drawn to measure hormone levels.
| Condition |
|---|
| Premenstrual Syndrome |
MedlinePlus related topics: Premenstrual Syndrome
Study Type: Observational
Study Design: Natural History
Official Title: The Treatment of Menstrually-Related Mood Disorders with Continuous Gonadal Steroid Replacement
Expected Total Enrollment: 35
Study start: March 28, 2000
Results from previous protocols (#90-M-0088 and 92-M-0174) have demonstrated that women with menstrually-related mood disorder (MRMD), but not women lacking this disorder, experience mood deterioration within approximately a week after exposure to either estradiol or progesterone in the context of gonadal suppression (induced by use of the depot gonadotropin releasing hormone agonist, leuprolide acetate). It is unknown whether this hormone-induced depression occurs consequent to changes in gonadal steroid levels or to simple exposure to levels above a critical threshold. Additionally, since the symptoms of depression stimulated by hormone addback appeared to remit by the fourth week of hormone administration, it is unclear whether continued administration of hormone would result in continued or repeated experience of depression or whether no further symptoms would appear subsequent to the initial precipitated episode. To address these points of uncertainty, we first will establish the efficacy of gonadal suppression in our MRMD subjects by administering depot leuprolide acetate for three months and then will administer both estradiol and progesterone in a continuous fashion for three months to determine whether maintenance of stable gonadal steroid levels will prevent the characteristic cyclic mood disorder.
Eligibility
Genders Eligible for Study: Female
Criteria
History within the last two years of at least six months with menstrually-related mood or behavioral disturbances of at least moderate severity--i.e., disturbances that are distinct in appearance and associated with a notable degree of subjective distress and interference with life activities.
Symptoms with a sudden offset and absence of significant symptomatology during the follicular phase.
Age 18-50.
Regular menstrual cycles (21-35 days in length), not pregnant, and in good medical health.
Medication free.
No subjects taking birth control pills or psychotropic agents (e.g. Antidepressants, anxiolytics, or lithium carbonate).
EXCLUSION CRITERIA:
Any patient with a current axis I psychiatric diagnosis will be excluded.
Location and Contact Information
Maryland
National Institute of Mental Health (NIMH), 9000 Rockville Pike, Bethesda, Maryland, 20892, United States; Recruiting
More Information
Detailed Web Page
Publications
Rubinow DR, Hoban MC, Grover GN, Galloway DS, Roy-Byrne P, Andersen R, Merriam GR. Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects. Am J Obstet Gynecol. 1988 Jan;158(1):5-11.
Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 1998 Jan 22;338(4):209-16.
Schmidt PJ, Nieman LK, Grover GN, Muller KL, Merriam GR, Rubinow DR. Lack of effect of induced menses on symptoms in women with premenstrual syndrome. N Engl J Med. 1991 Apr 25;324(17):1174-9.
Record last reviewed: March 9, 2005
Last Updated: March 29, 2005
Record first received: March 29, 2000
ClinicalTrials.gov Identifier: NCT00005011
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Not Signed In -


